# CROSS SYNC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cross-sync

- Industry: Healthcare IT
- Headquarters: Yokohama-shi, Japan
- Website: www.cross-sync.co.jp
- Total disclosed funding: $7.6M
- Latest round: Series A (Oct 6, 2025)
- Investors on record: 14

## About

Based in Yokohama, Japan, CROSS SYNC Inc. specializes in developing AI-driven healthcare solutions that enhance medical care delivery, particularly for critically ill patients by providing real-time data analysis and monitoring capabilities. CROSS SYNC Inc. focuses on creating advanced healthcare technology to improve patient outcomes. Founded in 2019 in Yokohama-shi, Japan, the company has engaged in 5 notable deals, with the most recent funding round being a Series A in October 2025, raising  JPY 230 million ?in?series A funding? from new investors PARAMOUNT BED CO., LTD and SBI Shinsei Corporate Investment, with participation from returning investor Allm Inc. The CEO, Shunsuke Takaki, leads the company in its mission to innovate healthcare solutions.     

CROSS SYNC specializes in the development of advanced AI-driven healthcare solutions, focusing on high-quality medical services akin to those found in intensive care units (ICUs). Their core offering includes a biometric monitoring application that assists healthcare professionals in managing critically ill patients by providing real-time data analysis, severity assessments, and facilitating rapid information sharing among medical teams. This technology aims to democratize access to ICU-level care across various healthcare settings, utilizing advanced systems that integrate artificial intelligence, big data, and semantic modeling to enhance diagnosis and treatment efficiency. The primary user base consists of hospitals and healthcare facilities within Japan, particularly in regions experiencing shortages of specialized medical staff. CROSS SYNC's revenue model is built on B2B transactions, primarily involving partnerships with healthcare institutions. The company generates income through the sales of its biometric monitoring application and consulting services aimed at optimizing healthcare operations and IT integration. Each partnership generally includes upfront licensing fees for the application and ongoing maintenance fees. The consulting services offer tailored insights to individual healthcare settings, further enhancing revenue through customized solutions, thus positioning the company competitively within the healthcare technology landscape. 

The company plans to use its proceeds from October 2025 funding to enhance its management structure.

## Funding rounds

- Series A, Oct 6, 2025, $1.6M — SBI Shinsei Corporate Investment, PARAMOUNT BED CO., LTD., Allm Inc.
- Series A, Jan 31, 2025, $1M — IT-Farm Corporation, Fukuda Denshi
- Series A, Aug 30, 2023, $1.6M — Mizuho Capital, Sony Innovation Fund, Future Creation Capital, Fukuda Denshi, YAGAMI
- Series A, Apr 7, 2023, $2.1M — IT-Farm Corporation, Yokohama Capital, Development Bank of Japan, Allm Inc.
- Series A, Mar 8, 2021, $1.4M — Toyota Tsusho, Development Bank of Japan, Konica Minolta, Inc., FINDEX Inc.

## Investors

- Toyota Tsusho — Series A
- Development Bank of Japan (https://capitalatlas.ai/funds/development-bank-of-japan) — Series A
- Konica Minolta, Inc. — Series A
- FINDEX Inc. — Series A
- IT-Farm Corporation (https://capitalatlas.ai/funds/it-farm-corporation) — Series A
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series A
- Allm Inc. — Series A
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series A
- Future Creation Capital (https://capitalatlas.ai/funds/future-creation-capital) — Series A
- Fukuda Denshi — Series A
- YAGAMI — Series A
- SBI Shinsei Corporate Investment (https://capitalatlas.ai/funds/sbi-shinsei-corporate-investment) — Series A
- PARAMOUNT BED CO., LTD. — Series A